Yorvipath 420 micrograms/1.4 mL solution for injection in pre‑filled pen, Yorvipath 168 micrograms/0.56 mL solution for injection in pre-filled pen, Yorvipath 294 micrograms/0.98 mL solution for injection in pre‑filled pen
ASND0035
Phase 3 small_molecule active
Quick answer
Yorvipath 420 micrograms/1.4 mL solution for injection in pre‑filled pen, Yorvipath 168 micrograms/0.56 mL solution for injection in pre-filled pen, Yorvipath 294 micrograms/0.98 mL solution for injection in pre‑filled pen for Chronic hypoparathyroidism is a Phase 3 program (small_molecule) at Ascendis Pharma Bone Diseases A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Ascendis Pharma Bone Diseases A/S
- Indication
- Chronic hypoparathyroidism
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active